Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Beijing Shijitan Hospital

2 abstracts

Abstract
A phase Ib study of JMT103, a receptor activator of NF-kB ligand (RANKL) antibody, in patients (pts) with bone metastases from solid tumors.
Org: Xuancheng People's Hospital, Beijing Shijitan Hospital, Handan First Hospital, Huizhou Central People’s Hospital,
Abstract
Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.
Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Shijitan Hospital, Capital Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 3D Medicine Inc.,